Charles River Labs had a significant pull back this year because the cell therapy sector did not advance as planned and the same would have happened to Cognate while waiting. Linda and NWBO investors didn’t need to carry that burden. Now if Linda Plans to merge Advent and NWBO when NWBO has moved well ahead in recognized value then that would be a boost for all shareholders. There will be a right time for that. Best wishes.
Market Data 
Markets 
AI
